Breaking News Bar

Business News and Information

Axsome Thera (NQ: AXSM )

44.76 +1.45 (+3.35%)

Streaming Delayed Price Updated: 4:00 PM EDT, Aug 9, 2022 Add to My Watchlist

Price and Volume

Volume	1,633,792
Open	41.00
Bid (Size)	44.25 (1)
Ask (Size)	44.68 (8)
Prev. Close	43.31
Today's Range	40.56 - 46.97
52wk Range	19.38 - 47.49
Shares Outstanding	38,913,550
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News

Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful

Today 9:08 EDT

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Axsome Therapeutics: Q2 Earnings Insights

Today 8:19 EDT

Axsome Therapeutics (NASDAQ:AXSM) reported its Q2 earnings results on Tuesday, August 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Performance

YTD	+18.32%	+18.32%
1 Month	+3.42%	+3.42%
3 Month	+66.89%	+66.89%
6 Month	+46.66%	+46.66%
1 Year	+63.72%	+63.72%

More News

7 Small-Cap Growth Stocks With 1,000% Upside Potential

July 31, 2022

Via InvestorPlace

Biotech Investors: August's Key PDUFA Catalysts You Must Know

July 31, 2022

Via Benzinga

Analyst Ratings for Axsome Therapeutics

June 29, 2022

Via Benzinga

Axsome Therapeutics Just Took Its Key Moving Averages — Here's Why

June 27, 2022

Via Investor's Business Daily

AXSOME THERAPEUTICS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Axsome Therapeutics, Inc. - AXSM

July 30, 2022

From Kahn Swick & Foti, LLC

Via Business Wire

Axsome Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022

July 28, 2022

From Axsome Therapeutics, Inc.

Via Globe NewsWire

7 Biotech Stocks to Buy for Q3

July 18, 2022

Via InvestorPlace

INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Axsome Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

July 12, 2022

From The Schall Law Firm

Via Business Wire

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Axsome Therapeutics, Inc. (AXSM)

July 11, 2022

From The Law Offices of Frank R. Cruz

Via Business Wire

INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Axsome Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

July 11, 2022

From The Schall Law Firm

Via Business Wire

AXSOME DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Axsome Therapeutics, Inc. and Encourages Investors to Contact the Firm

July 08, 2022

From Bragar Eagel & Squire, P.C.

Via Business Wire

NASDAQ:AXSM Investor Notice: Deadline on July 12, 2022 in Lawsuit Against Axsome Therapeutics, Inc.

July 08, 2022

Via SBWire

Do You Have Biotech FOMO? It Might Be Time To Pay Attention To These Names

July 06, 2022

Via Investor's Business Daily

Do You Have Biotech FOMO? Why Cogent, Arvinas And Others Are Flying

July 06, 2022

Via Investor's Business Daily

ROSEN, A LEADING LAW FIRM, Encourages Axsome Therapeutics, Inc. Investors with Losses Over $100K to Secure Counsel Before Important July 12 Deadline in Securities Class Action - AXSM

July 04, 2022

Via NewMediaWire

ROSEN, A LEADING NATIONAL FIRM, Encourages Axsome Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important July 12 Deadline in Securities Class Action - AXSM

June 29, 2022

Via NewMediaWire

What SVB Says On Axsome's Strategy Review On Sunosi For Sleeping Disorder

June 29, 2022

Via Benzinga

Global Pancreatic Cancer Therapeutics & Diagnostics Market Expected To Reach $5.6 Billion By 2027

June 28, 2022

Via FinancialNewsMedia

The Daily Biotech Pulse: CHMP Backs AstraZeneca's Breast Cancer Therapies, Ipsen Buys Epizyme, FDA Holds For Nuvation Bio, Astellas Studies

June 27, 2022

Via Benzinga

This Healthcare Stock Jumps Around 188%, Here's 83 Biggest Movers From Yesterday

June 28, 2022

Via Benzinga

Why Is NeuroSense Therapeutics Surging By 70%? 46 Stocks Moving In Monday's Mid-Day Session

June 27, 2022

Via Benzinga

EV Stocks TSLA, NIO, RIVN See Price Targets Slashed

June 27, 2022

Via InvestorPlace

Axsome Therapeutics Rallies 40% On FDA Product Label Proposal, But Analyst Remains Skeptical

June 27, 2022

Via Benzinga

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

bottom clear

About Us